NCT02153125

Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Tel-Aviv Sourasky Medical Center · Other Government
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to determine the efficacy and safety in treating patients with chronic central serous chorioretinopathy with the drug eplerenone.

Detailed description

* The goal of the study is to examine the short-term effects and safety of eplerenone, a systemic anti-aldosterone medication, in a group of patients with central serous chorioretinopathy (CSCR). * There is currently no standard treatment or therapy for chronic CSCR, a potentially debilitating eye disease. * There is evidence that high blood serum corticosteroid levels can cause or worsen CSCR * Eplerenone, a mineralocorticoid receptor antagonist, has been shown to be of visual and anatomic benefit in a small series of 4 patients with chronic CSCR, suggesting that decreasing mineralocorticoid action in the eye may improve signs and symptoms of CSCR * The study's aim is to evaluate a standardized dose of eplerenone in a controlled prospective fashion for chronic CSCR. * The study consists of taking a standard dose of eplerenone, 25mg once daily for a week, followed by 50mg once daily, for a total of 3 months * Patients will be monitored for efficacy and side effects from the beginning of treatment and for 6 months

Conditions

• Central Serous Chorioretinopathy

Interventions

Type	Name	Description
DRUG	Eplerenone

Timeline

• Start date: 2014-04-01
• Primary completion: 2015-06-01
• First posted: 2014-06-02
• Last updated: 2014-06-02

Locations

1 site across 1 country: Israel